Home › Kanser sa Baga › Illinois › Chicago
Pag-aaral pangklinika para sa Kanser sa Baga sa Chicago, IL
Isang pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Chicago. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Nagre-recruitPhase 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- at 1 pa
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Nagre-recruitPhase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- at 1 pa
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- University of Illinois Cancer Center, Chicago
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Nagre-recruitPhase 1/2
- University of Illinois Hospital & Health Sciences System ( Site 0044), Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Northwestern University, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Nagre-recruitPhase 3
- University of Illinois Chicago, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Registry for People With Lung Cancer
Nagre-recruitObservasyonal na pag-aaral
- Rush University Medical Center (Data collection only), Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Research Site, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Nagre-recruitPhase 2/3
- Rush University Medical Center, Chicago
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- University of Chicago Comprehensive Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Nagre-recruitPhase 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- Northwestern University, Chicago
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Xencor Investigative Site, Chicago
- Xencor Investigative Site, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Nagre-recruitPhase 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Nagre-recruit
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Nagre-recruitPhase 1/2
- University of Chicago, Chicago
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Nagre-recruitPhase 1/2
- Northwestern Memorial Hospital, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Nagre-recruitPhase 1/2
- Northwestern Memorial Hospital, Chicago
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Nagre-recruitPhase 2
- University of Illinois Cancer Center, Chicago
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Illinois at Chicago, Chicago
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Nagre-recruitPhase 2
- University of Chicago Medicine, Chicago
Lung Cancer Screening in High-risk Black Individuals
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Nagre-recruitObservasyonal na pag-aaral
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Chicago
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Nagre-recruitObservasyonal na pag-aaral
- University of Chicago, Chicago
Olaparib in Patients With HRD Malignant Mesothelioma
Nagre-recruitPhase 2
- University of Chicago Medical Center, Chicago
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Nagre-recruitObservasyonal na pag-aaral
- Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital), Chicago
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Nagre-recruitObservasyonal na pag-aaral
- Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Nagre-recruitPhase 2
- Northwestern University, Chicago
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
- Seattle, WA33 pag-aaral
Iba pang pag-aaral sa Chicago
- Non-Small Cell Lung Cancer61 pag-aaral
- Kanser sa Suso59 pag-aaral
- Kanser (lahat ng uri)51 pag-aaral
- Metastatic Cancer45 pag-aaral
- Kanser sa Prostate45 pag-aaral
- Obesity41 pag-aaral
- Kanser sa Ovary36 pag-aaral
- Colorectal Cancer34 pag-aaral
- Stroke34 pag-aaral
- Pagkabigo ng Puso31 pag-aaral
- Overweight29 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.